yahoo_financeOriginal article
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
Phase 2BGE-102Positive
AI Analysis
Summary
BioAge Labs, in partnership with HitGen, has dosed the first participant in a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor being developed for cardiovascular risk reduction.
Clinical Trial Data
Phase
Phase 2
Importance:6/10
Sentiment:
0.60
Phase 2clinical trialNLRP3 inhibitorcardiovascularfirst participant dosed
Related Companies
Read the original article
Published by yahoo_finance on July 14, 2026 1:30 PM